BioRestorative Therapies, Inc.
BRTX
$1.81
$0.000.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 391.00K | 401.00K | 377.00K | 174.10K | 149.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 391.00K | 401.00K | 377.00K | 174.10K | 149.50K |
| Cost of Revenue | 30.90K | 28.00K | 24.70K | 6.50K | -- |
| Gross Profit | 360.10K | 373.00K | 352.30K | 167.60K | 149.50K |
| SG&A Expenses | 6.63M | 6.60M | 7.68M | 8.82M | 9.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.64M | 11.96M | 12.46M | 13.08M | 13.70M |
| Operating Income | -12.25M | -11.56M | -12.09M | -12.90M | -13.55M |
| Income Before Tax | -12.10M | -8.98M | -9.65M | -3.79M | -5.47M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.10 | -8.98 | -9.65 | -3.79 | -5.47 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.10M | -8.98M | -9.65M | -3.79M | -5.47M |
| EBIT | -12.25M | -11.56M | -12.09M | -12.90M | -13.55M |
| EBITDA | -12.06M | -11.37M | -11.90M | -12.73M | -13.38M |
| EPS Basic | -1.47 | -1.17 | -1.46 | -0.28 | -1.25 |
| Normalized Basic EPS | -0.79 | -0.60 | -0.91 | -0.17 | -0.78 |
| EPS Diluted | -1.48 | -1.17 | -1.46 | -0.28 | -1.25 |
| Normalized Diluted EPS | -0.79 | -0.60 | -0.91 | -0.17 | -0.78 |
| Average Basic Shares Outstanding | 32.73M | 31.04M | 27.60M | 24.05M | 19.82M |
| Average Diluted Shares Outstanding | 32.73M | 31.04M | 27.60M | 24.05M | 19.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |